What happened with ADAG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Adagene is a clinical-stage biotechnology company developing antibodies that help the immune system fight cancer. Its lead candidate, ADG126 (muzastotug), remains in clinical trials. Its SAFEbody technology masks an antibody’s binding surface and is designed to activate it mainly around tumors, limiting activity in healthy tissues. The company has no approved medicines and no product-sales revenue.
Revenue comes mainly from upfront and milestone payments for granting partners rights to its technology or drug candidates. Under its Sanofi collaboration, Adagene generates masked antibodies through early research, while Sanofi pays for later development, regulatory approval and commercialization. Third Arc Bio also licenses SAFEbody technology for drug candidates it will develop and commercialize. These agreements provide for royalties if the resulting products reach the market and generate sales. Collaboration income helps pay for Adagene’s own research but only partly covers that spending.
The business depends heavily on ADG126’s development and on partners advancing licensed programs. Share issuance has been its principal source of funding. Adagene also relies on WuXi Biologics as its main manufacturer of clinical-trial materials. Medicines cannot be sold without regulatory approval, and its research in China faces approval or filing requirements for international projects involving human genetic resources and cross-border transfers of related samples or information.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Adagene’s results hinge on ADG126 clinical outcomes and licensing partners’ progress, including private Third Arc Bio’s development of its licensed masked CD3 programs.
Agenus Inc.’s lead cancer immunotherapy botensilimab competes with Adagene’s ADG126 in next-generation CTLA-4 treatments. Its efficacy and safety results in refractory colorectal cancer are a comparison to watch for ADG126.
Xilio Therapeutics, Inc. competes with Adagene on cancer immunotherapies designed to stay inactive until activated in tumors, including next-generation CTLA-4 antibodies and masked T-cell engagers. Results from its CTLA-4 program vilastobart offer a comparison for Adagene’s approach to improving efficacy and safety.
CytomX Therapeutics, Inc. competes with Adagene for cancer-treatment opportunities and pharmaceutical partners that fund or license antibody technology. Its PROBODY platform, like Adagene’s SAFEbody, masks a drug’s binding site until activation in tumors, making its clinical and partnership progress relevant comparisons.
Sanofi pays Adagene to generate masked antibodies and funds their later development and commercialization, so these programs can bring Adagene further milestone payments and royalties on sales. The medicines and vaccines maker exercised an option for a third SAFEbody research program in 2025, triggering another fee for Adagene.
Exelixis Inc licenses Adagene’s SAFEbody-generated antibodies to develop and commercialize cancer drugs, making its program decisions a source of payments and potential sales royalties for Adagene. Watch completion of discovery work for the additional antibody-drug conjugate target added in September 2025: it triggers the second installment payment.
BioAtla, Inc. competes with Adagene in tumor-selective cancer antibodies, including next-generation monospecific CTLA-4 programs. BioAtla designs its CAB antibodies to bind in acidic tumor conditions rather than normal tissue, offering a different approach to the same goal of reducing toxicity outside tumors.
Bristol Myers Squibb’s marketed cancer drug Yervoy sets a CTLA-4 benchmark for Adagene’s ADG126 and ADG116, while its clinical-stage urelumab competes with Adagene’s CD137 programs. The efficacy and toxicity of Yervoy-containing combinations are the concrete comparison for Adagene’s effort to develop safer CTLA-4 antibodies.
Merck & Co., Inc. supplies pembrolizumab for certain Adagene combination trials, but also develops quavonlimab to compete with Adagene’s next-generation CTLA-4 antibodies. For Adagene holders, the relevant results are those from its pembrolizumab combinations and Merck’s competing CTLA-4 program, rather than Merck’s broad medicine and vaccine sales.
Janux Therapeutics, Inc. competes with Adagene’s development and licensing of masked drugs that engage T cells against tumors. Watch JANX007’s Phase 1 results in adults with metastatic castration-resistant prostate cancer as a comparison for this approach; Janux has no approved products or product-sales revenue.
AstraZeneca’s marketed cancer drug Imjudo already competes in the CTLA-4 treatment market that Adagene’s ADG126 and ADG116 seek to enter. Its use in approved combinations provides an established treatment comparison for Adagene’s clinical efficacy and safety results.
Compass Therapeutics, Inc.’s CTX-471 competes with Adagene’s ADG206 and ADG106 in cancer antibodies that activate CD137. CTX-471’s clinical efficacy and safety results are the relevant comparison for these programs, rather than Adagene’s lead CTLA-4 candidate ADG126.
AbCellera Biologics Inc. and Adagene both help pharmaceutical partners discover antibodies in return for research or licensing payments, milestones and potential sales royalties. AbCellera’s partner-originated molecules reaching clinical trials are a concrete measure to watch for this business model, whose larger potential payments depend on successful drug development and sales.
Exelixis Inc earningsEXEL
Exelixis’s report can show whether discovery work on the additional antibody-drug conjugate target licensed from Adagene is complete and the second installment payment has been triggered.
Check whether discovery work on the added antibody-drug conjugate target is complete. Completion triggers the agreed second installment and brings Adagene collaboration revenue; if the work is not complete, that payment has not been triggered and should not be treated as income already received.
Compass Therapeutics, Inc. earningsCMPX
Compass Therapeutics’ report can show how its CD137 antibody CTX-471 is progressing, a comparison for Adagene’s ADG206 and ADG106.
Read CTX-471’s clinical efficacy together with its safety. Benefit with manageable side effects would support further work on activating CD137 and give ADG206 and ADG106 a benchmark; weak benefit or poor safety would leave greater uncertainty around that target, but would not establish how Adagene’s candidates will perform.
CytomX Therapeutics, Inc. earningsCTMX
CytomX Therapeutics’ report can show clinical and partnership progress for its PROBODY platform, a comparison for Adagene’s SAFEbody technology.
Look for clinical progress in PROBODY programs and signs that pharmaceutical partnerships are advancing. Progress on both fronts would show that tumor-activated antibody technology can still draw development and partner interest; little progress would leave its clinical value and appeal to partners less established, while SAFEbody would still need to prove itself through Adagene’s own programs.
Agenus Inc. earningsAGEN
Agenus’s report offers a comparison for how its botensilimab performs in refractory colorectal cancer, the same next-generation CTLA-4 treatment area as Adagene’s ADG126.
Read botensilimab’s efficacy alongside its safety in refractory colorectal cancer, meaning cancer that has not responded to treatment. Clear benefit with manageable side effects would support the case for next-generation CTLA-4 treatments and give ADG126 a useful benchmark; limited benefit or serious safety problems would weaken that case. These are not head-to-head trials, so the results are a comparison, not a direct test of ADG126.
